Opdivo

News

BMS has another Opdivo setback after liver cancer trial fail...

Bristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in advanced liver cancer.

Views & Analysis

R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo di...

Novartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company leaders give an overview of its drug pipeline.

News

BMS’ Opdivo fails late-stage brain cancer test

Bristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo into new types of cancer.

News

Keytruda gets okay from FDA for adjuvant melanoma

The US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who have had surgery but still show some evidence of cancer in their lymph nodes.

News

BMS pulls Opdivo/Yervoy in first-line lung cancer

Bristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line lung cancer market dominated by rival Merck & Co.

News

BMS gets new OK for Opdivo/Yervoy in kidney cancer

Bristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green light from the European Medicines Agency (EMA) for its use in renal

BMS has another Opdivo setback after liver cancer trial fail...

R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo di...

BMS’ Opdivo fails late-stage brain cancer test

Keytruda gets okay from FDA for adjuvant melanoma

BMS pulls Opdivo/Yervoy in first-line lung cancer

BMS gets new OK for Opdivo/Yervoy in kidney cancer

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Opdivo

Editor's Picks